- Home
- WLKP vs OPT Comparison
WLKP vs OPT Comparison
Compare WLKP & OPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WLKP
- OPT
- Stock Information
- Founded
- WLKP 2014
- OPT 1984
- Country
- WLKP United States
- OPT Australia
- Employees
- WLKP N/A
- OPT N/A
- Industry
- WLKP Major Chemicals
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WLKP Industrials
- OPT Health Care
- Exchange
- WLKP Nasdaq
- OPT Nasdaq
- Market Cap
- WLKP 853.5M
- OPT 855.6M
- IPO Year
- WLKP 2014
- OPT 2020
- Fundamental
- Price
- WLKP $24.18
- OPT $5.09
- Analyst Decision
- WLKP
- OPT Strong Buy
- Analyst Count
- WLKP 0
- OPT 1
- Target Price
- WLKP N/A
- OPT $12.00
- AVG Volume (30 Days)
- WLKP 35.1K
- OPT 40.1K
- Earning Date
- WLKP 02-24-2025
- OPT 03-03-2025
- Dividend Yield
- WLKP 7.79%
- OPT N/A
- EPS Growth
- WLKP 8.66
- OPT N/A
- EPS
- WLKP 1.75
- OPT N/A
- Revenue
- WLKP $1,143,109,000.00
- OPT $261,859.00
- Revenue This Year
- WLKP N/A
- OPT N/A
- Revenue Next Year
- WLKP $5.56
- OPT $46,864.26
- P/E Ratio
- WLKP $13.83
- OPT N/A
- Revenue Growth
- WLKP N/A
- OPT N/A
- 52 Week Low
- WLKP $21.19
- OPT $1.79
- 52 Week High
- WLKP $24.98
- OPT $6.30
- Technical
- Relative Strength Index (RSI)
- WLKP 54.49
- OPT 53.99
- Support Level
- WLKP $23.40
- OPT $4.77
- Resistance Level
- WLKP $24.98
- OPT $5.46
- Average True Range (ATR)
- WLKP 0.35
- OPT 0.32
- MACD
- WLKP -0.04
- OPT -0.11
- Stochastic Oscillator
- WLKP 49.05
- OPT 20.60
About WLKP Westlake Chemical Partners LP Common Units representing limited partner interests
Westlake Chemical Partners LP is a part of the chemical industry in the United States. Its operations are conducted through OpCo, it acquires and develop ethyelene production facilities, which convert ethane into ethylene. OpCo sells ethylene and its co-products such as propylene, crude butadiene, pyrolysis gasoline, and hydrogen to Westlake and other customers located in the United States. Its assets include three ethylene production facilities in Calvert City, Kentucky, and Lake Charles, Louisiana.
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.